Search

The development of effective antiepileptic drugs (AEDs) is crucial in the management of epilepsy, a chronic neurological disorder characterized by recurrent seizures. In order to identify potential AEDs, researchers employ a range of screening models that encompass both in-vitro and in-vivo approaches. These models provide valuable insights into the pharmacological properties and mechanisms of action of candidate compounds, aiding in the selection and optimization of drug candidates for further development. In-vitro screening models involve conducting experiments on isolated cells or tissues in controlled laboratory conditions. They allow researchers to examine the effects of AEDs on specific molecular targets involved in epileptogenesis, such as ion channels or neurotransmitter receptors. In-vitro models offer advantages such as cost-effectiveness, high throughput capacity, and the ability to study drug interactions with isolated components of the nervous system. Furthermore, they facilitate mechanistic investigations that elucidate the underlying pathways through which AEDs exert their antiepileptic effects. Hence, this review was focused for the various methods indicating the In-vitro and In-vivo pharmacological screening models for antiepileptic drugs. [ABSTRACT FROM AUTHOR]

Chinese Hamster Ovary (CHO) cells have proven to be a remarkable tool in the production of monoclonal antibodies, offering numerous advantages such as high expression levels and post-translational modifications. Through the utilization of advanced techniques, researchers have been able to optimize CHO cell cultures for enhanced antibody production. However, it is crucial to consider various factors such as media composition, cell line engineering, and bioprocess optimization to achieve optimal results. By carefully addressing these considerations, researchers can harness the full potential of CHO cells for the production of high-quality monoclonal antibodies. Thus, the field of biotechnology continues to advance at an astonishing pace, the production of monoclonal antibodies holds immense promise for revolutionizing medicine. These highly specific molecules have become indispensable tools in diagnostics, therapeutics, and research. However, their production requires careful consideration of various factors to ensure optimal yield and quality. In this article, we delve into the world of Chinese Hamster Ovary (CHO) cells and explore the techniques and considerations involved in harnessing their potential for monoclonal antibody production. [ABSTRACT FROM AUTHOR]

Probiotics, beneficial bacteria with significant therapeutic potential, have gained attention for addressing a range of health issues, including gastrointestinal disorders, immune deficiencies, and mental health concerns. This article delves into the expression and purification of recombinant microbial enzymes to harness the therapeutic potential of probiotics. Probiotics offer promise in promoting overall well-being and preventing diseases through their ability to modulate immune responses and enhance gut health. They have proven effective in alleviating symptoms related to conditions like irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and antibiotic-associated diarrhea. These live microorganisms, when administered in sufficient quantities, restore gut flora balance and modulate immune responses. By engineering probiotics to produce therapeutic enzymes that aid digestion or regulate gut microbiota, they can significantly contribute to digestive health and mitigate IBS and IBD symptoms. The expression and purification of recombinant microbial enzymes play a crucial role in enhancing probiotics' therapeutic capabilities, enabling tailored treatments for various health challenges. In summary, probiotics represent a promising frontier in therapeutic microbiology and biotechnology. Their multifaceted benefits, when combined with recombinant microbial enzyme expression and purification, hold immense potential for advancing the field of therapeutic probiotics and improving human health. [ABSTRACT FROM AUTHOR]

Introduction: The Tocilizumab (TCZ), a recombinant humanised anti-interleukin-6 receptor (IL-6R) monoclonal antibody, is primarily used to treat various autoimmune disorders specifically, rheumatoid arthritis. The usage of tocilizumab injection may reduce our capacity to combat infections brought on by bacteria, viruses, and fungi and raise our risk of developing a serious or potentially fatal illness that may spread throughout the body. To overcome these obstacles, the current work was concentrate on the Designing of a Chimeric Flagellin-mediated Tocilizumab Monoclonal Antibody for Autoimmune Disorders. The flagellum, a whip-like appendage that facilitates bacterial mobility, has a component protein called flagellin which has now been discovered to be a potent immune activator that shapes both the innate and adaptive immune systems in response to microbial infections. Methods: In this study, we were developed an In-silico, methods to design Chimeric-ScFv Monoclonal antibody which was based on speciallized linker to connect bacterial flagellin to Tocilizumab, between the heavy and light chains, yielding a chimeric antibody. Further the preliminary In-vitro cytotoxicity study attempt was on carried out on the MTT Viability assay of Chondrocytes and Fibroblasts in RA co-cultures with TCZ, Flagelline and TCZ+Flagelline Coadminstration. Results: Our findings suggest that the Flagelline mediated Tocilizumab monoclonal antibody, which was created by in-silico methods using chimeric ScFv, has good solubility, stability, and agonist and antagonist effects on TLR-5 and IL-6 respectivelly, based on binding and activation. The preliminary cytotoxicity study indicating the most active inhibition effects on fibroblast and chondrocytes with Co-adminstration of TCZ+Flagelline. Conclusion: Under this Proof of concept, the focus of future work will be based on the development, cloning, protein purification, characterization, and assessment of Chimeric flagelline mediated Tocilizumab monoclonal antibody for the treatment autoimmune disorders. [ABSTRACT FROM AUTHOR]

Western blotting is an important technique used to identify, quantify and determine the size of specific proteins. This technique makes it possible to identify the specific protein from a complex mixture. The central dogma is created by converting DNA into mRNA during transcription and helping to facilitate translations to induce protein synthesis. Blots, which frequently come after the use of gel electrophoresis are methods for putting DNA, RNA, and proteins onto a carrier for separation. For transferring DNA, the Southern blot and PCR methods are employed. The Northern blot, RT-PCR, and qPCR methods are utilized for transferring RNA. The transferring of protein can be utilized by the western blot method, which is now routinely used in drug discovery and scientific research, as well as for the identification of different medical disorders. This paper is based on key features of theoretical analysis of western blotting. [ABSTRACT FROM AUTHOR]